Almac Sciences to Invest in Continuous Flow Chemistry Equipment for New R&D Center

Article

Almac Sciences is investing in the expansion of its continuous flow chemistry equipment as an additional project to its previously announced £5-million (US$7-million) laboratory expansion.

Almac Sciences, a member of the Almac Group, announced on May 25, 2021 that it has invested £325,000 (US$459,000) in continuous flow chemistry equipment to further expand its most recent £5-million (US$7-million) laboratory expansion, which consisted of the construction of a two-story R&D center for flow chemistry, biocatalysis, and peptide technologies.

According to an Almac company press release, the new equipment will consist of microreactors, a photocatalysis flow rig, continuous stirred-tank reactors, a Vapourtec E series flow rig, in-house-built cryogenic rigs, microbubble and pressure technology, and spray drying, ultrafiltration/diafiltration, and liquid–liquid separation technology.

“The recent investment is critical for our strategic growth and highlights Almac Sciences’ commitment to offering our clients the best available technology solutions,” said Scott Wharry, Almac Sciences’ custom and flow chemistry manager, in the press release. “Our technology development has included the installation and commissioning of [a] high pressure hydrogenation pilot rig (with capability range up to 300 ºC and 100 Bar pressure) and, from Chemtrix, both lab- (Labtrix ) and kilo- (Protrix) scale flow rigs. These enhanced capabilities enable us to deliver superior solutions driving projects from proof-of-concept to kilo manufacture rapidly in response to our customers’ critical timelines.”

Source: Almac

Recent Videos
Drug Digest: Challenges and Triumphs in Next-Generation Biotherapeutic Development
Industry Outlook 2025: The Rising Prominence of AI in Pharma
Leroy Hood, MD, PhD
Adam Sherlock, CEO of Qinecsa, discusses the changing political landscapes in the US and Europe and how that may affect the bio/pharma industry.
Related Content